Combination Therapy for Ocular Melanoma
Author Information
Author(s): David P Mangiameli, Joseph A Blansfield, Stephan Kachala, Dominique Lorang, Peter H Schafer, George W Muller, David I Stirling, Steven K Libutti
Primary Institution: National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Hypothesis
Modulation of the tumor's microenvironment with multi-directed therapy, in the form of combinatory treatment with sorafenib and lenalidomide, will have improved efficacy in angiogenesis assays and a human ocular melanoma xenograft model.
Conclusion
Lenalidomide and sorafenib effectively target endothelial cells and inhibit tumor growth and metastasis in ocular melanoma.
Supporting Evidence
- Lenalidomide and Sorafenib inhibit HUVEC ability to migrate and form tubes.
- The combination of the agents improved the inhibition over either single agent.
- In a xenograft model, combination therapy inhibited tumor growth more effectively than single agents.
Takeaway
This study shows that using two medicines together can help stop eye cancer from growing and spreading better than using just one medicine.
Methodology
The study tested the effects of lenalidomide and sorafenib on human ocular melanoma cells and endothelial cells in vitro, ex vivo, and in vivo using a xenograft model.
Participant Demographics
The study involved female NCr-nu/nu mice for the xenograft model.
Statistical Information
P-Value
p < 0.0001
Confidence Interval
CI = 10.38–16.20
Statistical Significance
p < 0.004
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website